drugset / Trial / NCT00036231

Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction

NCT00036231 ↗

Phase 3 Terminated Repligen Corporation
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of the study is to determine the effect of multiple doses of secretin on autism.

Timeline

Start
2002-04
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject RG1068 Peptide — —

Indications